Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$106.12 USD

106.12
253,687

-1.97 (-1.82%)

Updated Jul 30, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

Is (MASI) Outperforming Other Medical Stocks This Year?

DexCom (DXCM) Hits 52-Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.

Masimo (MASI) Q2 Earnings and Revenues Beat Estimates

Masimo (MASI) delivered earnings and revenue surprises of 4.11% and 3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More

Solid growth in emerging markets is expected to be an added positive this earnings season.

Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

Masimo's (MASI) recent developments likely to show on second-quarter results.

Masimo (MASI) Q2 Earnings Preview: What's in the Cards?

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers

Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio

Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.

Here's Why You Should Buy Masimo (MASI) Stock Right Now

Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.

Urmimala Biswas headshot

Near-Term Outlook for Medical Instruments Industry Bleak

Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

DaVita Divests DMG to Optum, Boosts Kidney Care Services

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

Here's Why You Should Hold PerkinElmer (PKI) Stock for Now

PerkinElmer (PKI) raises earnings per share guidance for 2019.

Merit Medical Acquires Brightwater Medical for $35 Million

The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.

Here's Why You Should Hold Baxter International (BAX) for Now

Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.

Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment

Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.

Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring

Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.

Varian Medical Buys Endocare & Alicon to Boost Cancer Care

Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.

HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1

Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.

Why Is Masimo (MASI) Down 2.9% Since Last Earnings Report?

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cooper Companies (COO) Q2 Earnings & Revenues Top Estimates

Higher revenues, solid segmental performance and expansion in margins benefit Cooper Companies' (COO) Q2 earnings.

Veeva Systems (VEEV) Q1 Earnings Top Estimates, View Strong

Veeva Systems (VEEV) issues strong guidance for fiscal 2020.

NextGen's (NXGN) Q4 Earnings Top Estimates, Bookings Down Y/Y

NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.

Masimo's Technologies to be Deployed to Boost Pediatric Care

NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.

Globus Medical Reveals Positive Study Results for ExcelsiusGPS

Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure